On Monday, Shares of Barclays PLC (ADR) (NYSE:BCS), lost -1.05% to $13.22.
Barclays Bank PLC (“Barclays”) declared the launch of its consent solicitation (the “Consent Solicitation”) for select issues of iPath® Commodities Exchange-Traded Notes with the ticker symbols listed below (each, an “issue” and collectively, the “ETNs”).
Barclays is soliciting consents (the “Consents”) for the ETNs to the projected amendments described below (collectively, the “Projected Amendment”) separately for each issue of ETNs bearing the ticker symbols set out in the table below on the terms and conditions as set forth in the Consent Solicitation Statement, dated December 23, 2015 (the “Consent Solicitation Statement”) and the accompanying Voter Instruction Form (the “VIF”). Consents are being solicited from each person in whose name beneficial ownership of an issue of ETNs was recorded as of 5:00 p.m., Eastern Standard Time, on December 17, 2015, the record date for the Consent Solicitation.
The Consent Solicitation will expire on February 29, 2016, or such earlier date (the “Effective Time”) on which the approval of holders of a majority in aggregate principal amount (the “Required Consents”) of a particular issue is received and Barclays declares the Projected Amendment to be effective for such issue. Barclays may terminate or extend the Consent Solicitation at any time in its sole discretion.
Barclays PLC, through its auxiliaries, provides various financial products and services worldwide. It offers personal and corporate banking, mortgage, and wealth and investment administration services to individuals and businesses; consumer payments products and services to consumers and merchants; and retail and business banking, corporate and investment banking, and wealth administration and insurance services.
Shares of Boeing Co (NYSE:BA), inclined 0.70% to $144.53, during its last trading session.
Boeing (BA) issued the following statement following recently’s settlement declaration by the U.S. Federal Aviation Administration:
Boeing appreciates the dedication of both the Federal Aviation Administration and Boeing personnel who worked to reach the agreement declared recently. This agreement reflects Boeing’s deep and shared commitment to safety, quality and compliance – a commitment that has assisted make travel on large commercial airplanes the safest means of transportation in history.
Boeing believes that this agreement not only fairly resolves declared and potential civil penalty actions – most of which date back years, and two of which were formerly declared in 2012 and 2013 – but also will further enhance Boeing’s self-correcting quality and compliance systems. Under the terms of the agreement, Boeing has agreed to pay $12 million and make additional quality and compliance process improvements. Many of the improvements listed in the agreement have already been implemented or are in the process of implementation.
The Boeing Company, together with its auxiliaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide.
Finally, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), ended its last trade with -0.59% loss, and closed at $65.93.
Takeda Pharmaceutical Company Limited (TOKYO:4502) and Teva Pharmaceutical Industries Ltd. (TEVA) (TEVA.TA) made the below follow-up declaration regarding the overview of their new business venture in Japan, which was initially revealed on November 30, 2015 in the press release titled, “Teva and Takeda establish unique partnership to meet the wide-ranging needs of patients and growing importance of generic medicines use in Japan”.
The new business venture, to be established in or after April 2016, will deliver Teva’s high-quality generic medicines and some of Takeda’s long listed products to patients and healthcare professionals in Japan, leveraging Takeda’s corporate brand and unique distribution network in Japan and Teva’s wide product portfolio and cutting-edge business efficiency.
The major long listed products of Takeda to be transferred to the new business venture in FY2016 are BLOPRESS, TAKEPRON and BASEN. Total sales of the products to be transferred in FY2016 were 125 billion yen in FY2014, which was 7% of Takeda’s global revenue. As a result of the transaction, Takeda’s FY2016 revenue is estimated to decrease by about 50 billion yen, based upon current assumptions. LEUPLIN remains at Takeda, as a product of Takeda Oncology.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
